Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.51 USD | -1.10% | +2.04% | -8.15% |
Apr. 17 | Deutsche Bank Upgrades Medical Properties Trust to Hold From Sell, Adjusts PT to $5 From $2 | MT |
Apr. 15 | Sector Update: Financial Stocks Sliding Late Afternoon | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Its low valuation, with P/E ratio at 8.71 and 8.21 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company appears to be poorly valued given its net asset value.
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialized REITs
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.15% | 2.73B | C | ||
+4.62% | 55.76B | A- | ||
-11.72% | 17.72B | A- | ||
-5.05% | 13.23B | A | ||
+1.40% | 7.68B | B | ||
-16.54% | 5.39B | B- | ||
+8.62% | 3.28B | C- | ||
-5.42% | 3.06B | B+ | ||
+12.61% | 2.73B | C- | ||
-13.17% | 2.43B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MPW Stock
- Ratings Medical Properties Trust, Inc.